{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ACT-1","nct_id":"NCT00646854","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=act-1-nct00646854. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ACT-1","arms":[{"description":null,"label":"Arm A","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"Arm B","type":"EXPERIMENTAL"}],"collaborators":["GCP-unit at Aarhus University Hospital, Aarhus, Denmark"],"completion_date":{"date":"2016-12-31","type":"ACTUAL"},"conditions":["Lymphoma, T-Cell, Peripheral"],"enrollment":{"count":136,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab","otherNames":[],"type":"DRUG"},{"name":"CHOP14 chemotherapy (see specification under Arm B) plus G-CSF","otherNames":[],"type":"DRUG"}],"last_update":"2019-03-01","lead_sponsor":"Aarhus University Hospital","official_title":"A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2016-12-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-free Survival","timeFrame":"The EFS is defined by the time between day of randomization until an event occurs, up to 96 months"}],"references":[],"start_date":{"date":"2008-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Alemtuzumab and CHOP in T-cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT00646854"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/act-1-nct00646854"}